Apigenin appears in allergy research for a specific reason: it acts on mast cells, the immune cells that release histamine when an allergen binds IgE on their surface. That’s the same cell type antihistamines work downstream of. The research is genuinely mechanistic and reasonably consistent across models — and it is also entirely animal and cell-based, at injected doses, with no human allergy trial behind it. Here’s what was actually measured.
Key Takeaways
- In two separate mouse models of ovalbumin-induced allergic rhinitis, injected apigenin reduced sneezing, nasal rubbing, and discharge, alongside lower serum histamine and allergen-specific IgE.
- The proposed mechanism is a shift in Th1/Th2 balance — suppressing the Th2 side (IL-4, IL-5, IL-13, GATA3, STAT6) while raising Th1 markers (IFN-gamma, T-bet).
- A second mechanism, TLR4/MyD88/NF-kB inhibition, was demonstrated in human mast cells (HMC-1) alongside direct suppression of histamine and beta-hexosaminidase release.
- A 2025 ulcerative colitis study showed apigenin suppressing mast cell degranulation through the MRGPRX2 receptor — the pathway behind non-IgE (“pseudo-allergic”) reactions.
- Every one of these used injected apigenin in animals or direct application to cells. No human trial has tested oral apigenin for allergic rhinitis, hay fever, or any allergy outcome.
Two Allergic Rhinitis Models, Similar Results
The most direct evidence comes from two independent mouse studies using the same standard model: BALB/c mice sensitized to ovalbumin, then challenged intranasally to provoke allergic rhinitis. A 2020 study gave apigenin by intraperitoneal injection at 5, 10, and 20 mg/kg. At the two higher doses, the classic nasal symptoms — sneezing, rubbing, and discharge — were significantly reduced. So were serum histamine, OVA-specific IgE, total IgE, IgG1, and beta-hexosaminidase, which is the standard laboratory marker of mast cell degranulation.[1]
A 2023 study replicated the animal findings and added a human cell component, using the HMC-1 human mast cell line stimulated with compound 48/80 and lipopolysaccharide. Apigenin significantly inhibited compound 48/80-induced release of both beta-hexosaminidase and histamine from those cells, and suppressed inflammatory cytokine secretion by acting on the TLR4/MyD88/NF-kB pathway. In the mice, it again reduced OVA-specific IgE, histamine, eosinophil cationic protein, and nasal eosinophil infiltration.[2] Two labs, two mechanisms described, convergent results — that’s a stronger preclinical position than most flavonoid claims have.
The Th1/Th2 Framing, and What It Actually Means
Both studies converge on the same immunological explanation. Allergic disease is characterized by a Th2-skewed immune response: high IL-4, IL-5, and IL-13, driven by the transcription factor GATA3 and the signaling protein STAT6. Apigenin treatment lowered all of those and raised the opposing Th1 markers, IFN-gamma and T-bet.[1][2] The 2023 study went further and measured the actual ratio of Th1 to Th2 cells in circulating blood cells, finding it shifted toward Th1 after treatment.[2]
Worth being precise about one detail, because it cuts against a simple story: the 2020 study reported that apigenin decreased IFN-gamma in nasal lavage fluid, while describing Th1 activation systemically via T-bet and splenic markers.[1] The overall anti-allergic effect was consistent; the cytokine picture is not uniformly “Th1 up everywhere.” That kind of detail tends to get flattened in supplement marketing into “apigenin rebalances your immune system,” which oversells a set of measurements taken in sensitized mice.
The Mast Cell Angle Beyond IgE
A 2025 study in Phytomedicine examined a different and less familiar route to mast cell activation. Not all mast cell degranulation runs through IgE; the receptor MRGPRX2 in humans (MrgprB2 in mice) triggers degranulation in response to certain peptides and drugs, producing reactions that look allergic but aren’t classically IgE-mediated. In a mouse model of ulcerative colitis, apigenin suppressed mast cell degranulation and blocked the self-reinforcing loop between the peptide PAMP-12 and this receptor, reducing colon tissue damage and inflammatory cell infiltration. The effect depended on the receptor: the researchers used mice with MrgprB2 conditionally knocked out in mast cells to establish that.[3]
That study was about colitis, not allergy. But it’s relevant here because it demonstrates apigenin acting on mast cell degranulation through a second, independent pathway — which is more interesting than a compound that only works one way in one tissue.
What Doesn’t Transfer to a Supplement Bottle
Every result above used either direct application to cultured cells or intraperitoneal injection into animals. Injection bypasses the digestive tract entirely, and oral apigenin has poor absorption — the central limitation running through nearly all apigenin research. The 5 to 20 mg/kg mouse doses also don’t translate to human milligram amounts by simple arithmetic; body-surface-area scaling puts them well above typical supplement doses, and even then the delivery route differs.
The honest summary is that apigenin has a plausible, multi-mechanism preclinical case for anti-allergic activity, and zero human evidence that swallowing a capsule produces any of it. If you have allergic rhinitis, the interventions with actual human trial data behind them — intranasal corticosteroids, second-generation antihistamines, allergen immunotherapy — are in a different evidence category entirely. Apigenin is not a substitute for any of them, and anyone with asthma or a history of anaphylaxis should not be experimenting with supplements in place of prescribed treatment.
Bottom Line
Apigenin reduced allergic rhinitis symptoms, serum histamine, and allergen-specific IgE in two independent mouse studies, and directly suppressed histamine and beta-hexosaminidase release from human mast cells in culture. Two mechanisms are described: a Th2-to-Th1 immune shift, and TLR4/MyD88/NF-kB inhibition, with a third route through the MRGPRX2 receptor shown in a separate colitis model. All of it is preclinical, all of it used injection or direct cell exposure, and none of it has been tested in a person with allergies taking apigenin by mouth.
References
- Chen F, He D, Yan B. Apigenin Attenuates Allergic Responses of Ovalbumin-Induced Allergic Rhinitis Through Modulation of Th1/Th2 Responses in Experimental Mice. Dose-Response (2020). PMID 32165873
- Li H, Zhang H, Zhao H. Apigenin attenuates inflammatory response in allergic rhinitis mice by inhibiting the TLR4/MyD88/NF-kB signaling pathway. Environmental Toxicology (2023). PMID 36350155
- Huang Y, Wang N, Ji X, et al. Apigenin ameliorates inflamed ulcerative colitis by regulating mast cell degranulation via the PAMP-MRGPRX2 feedback loop. Phytomedicine (2025). PMID 40054174
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
